Neuroendocrine Gene Transcript Analysis of Blood Identifies Stable or Progressive NET Disease Treated with Somatostatin Analogs. Abstract #1195

Introduction: An issue in NET management is defining stable or progressive disease and effective treatment. An alternative to RECIST criteria is a sensitive, reproducible blood biomarker test. Somatostatin analogs (SSA) are a chief therapy but efficacy is subjective and based on symptom control and imaging.
Aim(s): Investigate the utility of a PCR-based 51 gene signature (NETest) and CgA as biomarkers to define SSA efficacy.
Materials and methods: GEP-NETs (n=35) M:F 12:23; median age 58, small intestine n=29, pancreas n=3, rectum n=3 were evaluated. qRT-PCR measured transcript levles and ELISA (DAKO) for CgA. Clinical status and imaging was assessed. NETest defines disease activity risk scaled 0-100%; low and high activity cutoff at 47%.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Daniele Alaimo
Keywords: Biomarker, SSA

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1212 Circulating Gene Transcript Analysis of Pancreatic NETs
Introduction: PNETs are aggressive with poor survival. Therapeutic agents are available but efficacy determination is limited by imaging insensitivity and the lack of effective blood biomarkers.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Daniele Alaimo
Authors: Kidd M, Modlin I, Drozdov I, Alaimo D, ...
Keywords: PNET, NETest, PCR
#897 A Molecular Multi-Transcript Gene Blood Signature Significantly Outperforms Chromogranin A (CgA) in the Detection of Gut Neuroendocrine Tumors (NETs)
Introduction: A key issue in NET management is the need for a specific and sensitive biomarker to detect disease and assess treatment. CgA is widely utilized but has limitations.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Professor Irvin M Modlin
Authors: Modlin I M, Kidd M, Drozdov I, Alaimo D, ...
Keywords: biomarker, CgA, NET, PCR
#913 A PCR-Based Multigene Transcript Analysis Blood Test Outperforms Chromogranin A in the Detection of Gastrointestinal and Pancreatic Neuroendocrine Tumors and is Unaffected by PPI Use or Hypertension
Introduction: A critical requirement in the management of gut NETs is a blood biomarker test that is sensitive, specific and reproducible.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Professor Irvin M Modlin
Keywords: biomarker, CgA, NET, PCR
#2083 Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study
Introduction: Predicting treatment response at an early stage in the treatment algorithm for NET is highly desirable.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Associate prof, Magnus Kjellman
#1228 Measurement of Blood Gene Transcripts Defines PRRT Therapeutic Efficacy
Introduction: PRRT is an effective therapy for NETs since the majority over-express SSRs. Typically, well or moderately differentiated NETs (G1/G2) are treated. Imaging and CgA are used to evaluate response but both RECIST criteria and CgA have limitations.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Paganelli G, Kidd M, Severi S, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.